Research field (2)：
Tumor diagnostics and therapeutics
, Respiratory medicine
Research keywords (4)：
Lung Cancer
, Internal Medicine
, Respiratory Medicine
, Clinical Oncology
Research theme for competitive and other funds (1)：
2020 - 2024 肺癌に対する放射線療法と免疫療法の有効性の関連解析および最適な治療法の開発
Papers (54)：
Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, et al. Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]. Lung cancer (Amsterdam, Netherlands). 2024. 188. 107450-107450
Moriyasu Anai, Koichi Saruwatari, Kosuke Imamura, Kosuke Fujino, Takayuki Jodai, Shinya Sakata, Shinji Iyama, Yusuke Tomita, Sho Saeki, Hidenori Ichiyasu, et al. Negative impact of ratio of the microvascular area to tumor area on the response to EGFR-TKI in non-small cell lung cancer with an EGFR mutation. Journal of Thoracic Disease. 2024. 16. 2. 1151-1160
Yusuke Tomita, Shinya Sakata, Kosuke Imamura, Shinji Iyama, Takayuki Jodai, Koichi Saruwatari, Shohei Hamada, Kimitaka Akaike, Moriyasu Anai, Kazuaki Fukusima, et al. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations. Cancers. 2023. 16. 1. 47-47
Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, et al. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP). Lung Cancer. 2023. 186. 107426-107426
